CTXR 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• On July 21, 2026, Citius Oncology announced the expansion of its commercial organization to include 21 additional commercial field-based professionals and the addition of eight medical science liaisons dedicated to supporting complex clinical practitioner engagement and patient care. All personnel w…

• On August 14, 2026, Citius Oncology provided an update on the U.S. commercial launch of LYMPHIR highlighting increased institutional availability for LYMPHIR, accelerating institutional vial orders and the expansion to a full commercial field organization.

• ●44 institutions have ordered LYMPHIR since its launch including; academic oncology centers, leading National Comprehensive Cancer Network (NCCN) institutions, and community infusion centers;

• ●Increased the number of new ordering institutions by 80% in the quarter ended June 30, 2026 compared to the quarter ended March 31, 2026;

• ●Grew the number of vials ordered by institutions from wholesalers by 31% in the quarter ended June 30, 2026, compared to the quarter ended March 31, 2026, 926 vs. 708 vials respectively;

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• Research and development costs for Mino-Lok decreased by $56,092 to $66,478 for the three months ended March 31, 2026, as compared to $122,570 for the three months ended March 31, 2025 primarily related to lower costs related to Mino-Lok combination studies. In November 2024, the Company held a Type…

• Research and development costs for LYMPHIR decreased by $2,085,664 to $1,555,815 during the three months ended March 31, 2026, as compared to $3,641,479 for the three months ended March 31, 2025 was primarily related to expense recognized in the three months ended March 31, 2025 for a pre-license in…

• Stock-based compensation expense for the three months ended March 31, 2026, includes $261,565 for Citius Pharma options, $1,858,443 for Citius Oncology options and $1,668,267 for Citius Oncology restricted stock awards. Stock-based compensation expense for the three months ended March 31, 2025 inclu…

• For the three months ended March 31, 2026, interest income was $53,584, as compared to interest income of $13,413 for the three months ended March 31, 2025. We have invested the remaining proceeds of our equity offerings in money market accounts.

• We recognized a gain of $3,833,277 for the three months ended March 31, 2026, in connection with the sale of certain New Jersey income tax net operating losses to a third party under the New Jersey Technology Business Tax Certificate Transfer Program.

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• Our majority-owned subsidiary, Citius Oncology, has substantial indebtedness and debt service obligations, which could adversely affect our financial condition.

• Citius Oncology has incurred significant indebtedness under the Loan Agreement, which features a tiered tranche structure with a floating interest rate subject to a floor of 12.75% per annum. During the interest-only period, Citius Oncology will not reduce the outstanding principal balance of the lo…

• Additional funding tranches under the Loan Agreement are conditioned upon the achievement of specified milestones, and there can be no assurance that such milestones will be achieved.

• The availability of Tranche 2 and Tranche 3 under the Loan Agreement is conditioned upon Citius Oncology’s achievement of specified net revenue and liquidity milestones. If it fails to achieve the required milestones within the applicable time periods, Tranche 2 and/or Tranche 3 will not become avai…

• Citius Oncology’s failure to access these additional tranches could significantly impair its ability to fund ongoing operations, pursue growth initiatives, or meet its working capital requirements. In such event, Citius Oncology may be required to seek alternative sources of financing, which may not…